Table 1. Effect of Drs B2 on proliferation of human tumor and non tumor cells.
Cell name | Cell type | GI50 | |
[µM of Drs B2 ± SD] | |||
tumor | PC3 | prostate adenocarcinoma | 1.24±0.23 |
LNCAP | prostate adenocarcinoma (adrenogen sensitive) | 0.31±0.15 | |
DU145 | prostate carcinoma (non adrenogen sensitive) | 0.91±0.04 | |
MDA-MB231 | mammary carcinoma | 8.06±0.50 | |
RAJI | B-lymphoma | 2.57±0.75 | |
immortalized | LB-EBV | B-lymphoblastoids, transformed by Epstein-Barr virus | 1.09±0.56 |
HTK | corneal fibroblasts | 1.80±0.40 | |
PNT1A | prostatic cell line (non adrenogen sensitive) | 0.38±0.05 | |
primary | G1947 | stromal prostate fibroblasts | * |
FD | skin fibroblasts | * |
All the cells used are from human origin, the names of cell lines or types and their tissues of origin are indicated. Proliferation of each cell type was performed in plastic 24 wells plates (1.91 cm2; cell density of 1×104 cells/well/0.5 mL). On the first, third and fifth day after plating the cells were treated with Drs B2 at different concentrations ranging from 0 till 15 µM. Twenty four hours after the last treatment cell counting was performed with crystal violet staining for adherent cells and with a Malassez Hemacytometer for non-adherent cells. Results are represented in peptide concentration inhibiting 50% of the cell growth GI50 ± SD of at least three determinations.
No cytotoxicity observed when cells were treated with a maximal concentration of 15 µM of Drs B2.